ArticleInternational journal of tryptophan research : IJTR2026
Tryptophan Supplementation Reduces Schizophrenia-Like Symptoms in Apomorphine Treated Rats: Role of D2, GABA, and Glutamate Receptor Expression.
Article in International journal of tryptophan research : IJTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a multifaceted neuropsychiatric disorder characterized by disruptions in dopaminergic, GABAergic, and glutamatergic signaling pathways. While conventional antipsychotics primarily target dopamine D2 receptors, exhibit limited efficacy to alleviate cognitive deficits and negative symptoms and are associated with extrapyramidal side effects. Tryptophan (Trp), the essential amino acid precursor to serotonin, is critical modulator of these circuits. Serotonin acts as a brake on dopamine release and receptor activity. This study investigates the therapeutic potential of Trp supplementation in reducing schizophrenia-like symptoms in apomorphine-treated rats, focusing on the mRNA expression of D2, GABA, and glutamate receptors in nucleus accumbens and caudate. Apomorphine, a dopamine agonist, induces hyperdopaminergic activity, mimicking schizophrenia-like behaviors. In the present study, rats were divided into control, apomorphine-treated, Trp-supplemented and apomorphine plus Trp treated groups. Trp was administered at two different doses (25 and 50 mg/kg). Behavioral assessments were conducted in novel and familiar environments, Morris water maze and elevated plus maze to evaluate motor activity, learning and memory, and anxiety respectively. Results demonstrated that Trp supplementation significantly ameliorated the schizophrenia-like symptoms induced by apomorphine, exhibiting a distinct biphasic pattern: the 25 mg/kg dose was consistently more effective than the 50 mg/kg dose. Specifically, the low dose Trp reduced hyperactivity, improved cognitive performance and anxiolytic effects. In contrast, the 50 mg/kg dose showed a diminished therapeutic effect, likely due to competitive kynurenine pathway activation. Molecular analysis showed that optimal tryptophan treatment decreased the mRNA expression of D2 receptors, enhanced GABA receptor mRNA expression, and stabilized glutamate receptor mRNA levels in key brain regions. These findings suggest that low dose tryptophan supplementation may offer a promising adjunctive treatment for schizophrenia by restoring transcriptional balance of critical neurotransmitter systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.